中枢神经系统的真菌感染采用传统的抗真菌制剂治疗有疗程长、毒性大、疗效低等缺点。脑室出血、阻塞、细菌感染等并发症的发生率高达85％,还可导致不可逆性神经损害。酮基康拉唑(ketoconazole)系一种供口服的咪唑类新制剂。已报告其对各种非脑膜型真菌病有效。鉴于用常规剂量(200或400mg/d)时病人脑脊液中药物浓度很低,甚至无法测出。又因该药毒性低及安全 Central nervous system fungal infections with traditional antifungal agents have a long course of treatment, toxicity, low efficacy and other shortcomings. The incidence of ventricular hemorrhage, obstruction, bacterial infections and other complications as high as 85%, can also lead to irreversible nerve damage. Ketoconazole (ketoconazole) is a new preparation of imidazole for oral administration. It has been reported to be effective against various non-meningeal fungal diseases. Given the very low concentration of the drug in the cerebrospinal fluid of patients at regular doses (200 or 400 mg / d), it is not even detectable. Because of the drug toxicity and safety